Phase 3 Prostate Cancer Trial, Recruiting NCT06972511 Sponsor: RenJi Hospital Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT06972511
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be younger than 75 years old.
  • Your quality of life score, measured using a standard questionnaire called the EORTC QLQ-C30, must be at a level of 2 (confirm with trial site).
  • You are expected to have a life expectancy of at least 10 years.
  • You have been diagnosed with prostate cancer that has spread to a limited number of sites in the body (called oligometastatic prostate cancer), based on clinical and tissue assessments.
  • Your doctors have determined that you are suitable to receive both radiotherapy (radiation treatment) and surgery to remove the prostate.
  • You are willing to take part in the study and sign a consent form before joining.

Who may not be able to join:

  • You have had a bone fracture caused by the cancer.
  • You are unable to receive radiotherapy (radiation treatment) for any reason.
  • The cancer has spread to internal organs such as the liver or lungs (known as visceral metastasis).
  • You have a serious active infection.
  • You have a history of blood clots in veins or arteries (thromboembolism).
  • You have heart or cardiovascular problems that are not well managed or under control.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8613916989510

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
20 August 2023
Est. completion
30 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Time to hormone-resistant prostate cancer (TTCRPC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov